Table 2.
Disease activity and quality of life in Crohn’s disease.
| BMI category | Normal (n = 977) | Obese (n = 194) | p |
|---|---|---|---|
| Fistulas | |||
| Perianal | 237 (24.3) | 50 (25.8) | 0.654 |
| Any | 323 (33.1) | 65 (33.5) | 0.904 |
| Abscess | |||
| No | 744 (76.2) | 148 (76.3) | |
| Yes | 233 (23.8) | 46 (23.7) | 0.967 |
| Intestinal stenosis | |||
| No | 556 (56.9) | 130 (67.0) | |
| Yes | 421 (43.1) | 64 (33.0) | 0.009 |
| Behaviour | |||
| B1 (inflammatory) | 364 (37.3) | 87 (44.9) | |
| B1p (B1 + perianal disease) | 144 (14.7) | 31 (16.0) | |
| B2 (stricturing) | 200 (20.5) | 28 (14.4) | |
| B2p (B2 + perianal disease) | 124 (12.7) | 20 (10.3) | |
| B3 (penetrating) | 72 (7.4) | 11 (5.7) | |
| B3p (B3 + perianal disease) | 73 (4.5) | 17 (8.8) | 0.195 |
| EIM | |||
| Arthritis | 451 (46.2) | 111 (57.2) | 0.005 |
| Uveitis/iritis | 104 (10.6) | 27 (13.9) | 0.187 |
| PG | 12 (1.2) | 2 (1.0) | 1.000 |
| EN | 67 (6.9) | 19 (9.8) | 0.174 |
| Oral ulcers | 141 (14.4) | 25 (12.9) | 0.573 |
| AS | 56 (5.7) | 19 (9.8) | 0.035 |
| PSC | 8 (0.8) | 1 (0.5) | 1.000 |
| Any | 531 (54.4) | 123 (63.4) | 0.020 |
| CDAI score | 20, 6–53 | 33, 6–69 | |
| (median, IQR, range) | 0–345 | 0–280 | 0.001 |
| Number of soft stools | 4, 0–14 | 8, 0–25 | |
| (median, IQR, range) | 0–140 | 0–100 | 0.001 |
| Disease location at diagnosis | |||
| L1 (ileal) | 237 (24.3) | 28 (14.4) | |
| L2 (colonic) | 195 (20.0) | 45 (23.2) | |
| L3 (ileo-colonic) | 449 (46.0) | 88 (45.4) | |
| L4 (upper GI only) | 10 (1.0) | 1 (0.5) | |
| Unknown/Unclear | 86 (8.8) | 32 (16.5) | 0.002 |
| CRP in mg/l | 3, 1–7 | 5, 3–12 | |
| (median, IQR, range) | 0–155 | 0–245 | <0.001 |
| Faecal calprotectin in ug/g | 105, 32–293 | 139, 61–296 | |
| (median, IQR, range) | 0–3500 | 15–1835 | 0.467 |
| IBDQ Bowel score | 59, 51–65 | 57, 49–63 | |
| (median, IQR, range) | 22–70 | 30–70 | 0.071 |
| IBDQ Systemic score | 26,21–30 | 23, 19–28 | |
| (median, IQR, range) | 7–35 | 9–35 | 0.001 |
| IBDQ Emotional score | 68, 57–75 | 66, 56–76 | |
| (median, IQR, range) | 14–84 | 28–84 | 0.922 |
| IBDQ Social score | 34, 28–35 | 31, 26–35 | |
| (median, IQR, range) | 6–35 | 7–35 | 0.005 |
| IBDQ Total score | 185, 159–202 | 177, 150–198 | |
| (median, IQR, range) | 66–224 | 78–223 | 0.091 |
| SF36 Physical score | 51, 44–56 | 47, 36–53 | |
| (median, IQR, range) | 16–72 | 13–67 | <0.001 |
| SF36 Mental score | 47, 38–54 | 48, 38–55 | |
| (median, IQR, range) | 10–66 | 18–66 | 0.285 |
| Medical resources consumption (in last 3 months) | |||
| Hospitalization | 71 (14.7) | 21 (21.0) | 0.114 |
| Outpatient visit | 164 (33.7) | 28 (28.3) | 0.297 |
| Work absence (in last 3 months) | |||
| No | 315 (86.5) | 45 (80.4) | |
| Yes | 49 (13.5) | 11 (19.6) | 0.218 |
AS: axial spondylarthropathy; BMI: body mass index; CDAI: Crohn’s Disease Activity Index; CRP: C-reactive protein; EIM: extraintestinal manifestation; EN: erythema nodosum; GI: gastro-intestinal; IQR: interquartile range; PG: pyoderma gangrenosum; PSC: primary sclerosing cholangitis.